Harrow, Inc. Common Stock HROW

Harrow, Inc. is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the North American market. The Company offers a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE, BYQLOVI and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.

• GlobeNewswire Inc. 20 jul

  Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting

  Harrow announced presentations of three studies supporting its ophthalmic products IHEEZO (chloroprocaine HCl ophthalmic gel) and BYOOVIZ (ranibizumab-nuna biosimilar) at the ASRS 2026 Annual Meeting. Interim findings from a randomized study showed IHEEZO demonstrated encouraging trends toward less post-injection pain and better patient experience compared to subconjunctival lidocaine. A large real-world analysis of nearly 20,000 injections found no increased endophthalmitis risk with IHEEZO. The company continues enrollment in the QUELL clinical trial with topline data expected in Q4 2026.

  

• GlobeNewswire Inc. 10 jun

  Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare

  Harrow announced the re-launch of VERKAZIA, a prescription therapy for vernal keratoconjunctivitis (VKC), a chronic allergic eye disease primarily affecting children. The company is implementing a comprehensive commercial strategy focused on physician education, patient access, and affordability. VERKAZIA is a calcineurin inhibitor that addresses underlying inflammatory mechanisms and reduces the need for steroid rescue therapy, which carries risks like glaucoma and cataract formation.